

# Clinical Policy: Fecal Incontinence Treatments

Reference Number: WNC.CP.125

Last Review Date: 05/22

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Note:** When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

---

## Description

Fecal incontinence is defined as the uncontrolled passage of feces or gas over at least 1 month's duration, in an individual of at least four years of age, who had previously achieved control. It has a negative impact on self-esteem and quality of life.<sup>1</sup> The choice of therapy depends upon the etiology of incontinence, the anatomy of the sphincters, and also on the effect of incontinence on the quality of life.

## Policy/Criteria

- I. It is the policy of WellCare of North Carolina® that procedures to treat fecal incontinence are medically necessary when meeting the following:
  - A. Severe, chronic fecal incontinence (defined as greater than two incontinent episodes on average per week and duration of incontinence greater than six months) that has not responded adequately to conservative treatments (e.g. pharmacotherapy, dietary management, strengthening exercises);
  - B. Age  $\geq$  4 years and the member has previously achieved bowel control;
  - C. Requested procedure meets **one** of the following:
    1. Sacral nerve stimulation for a weak but structurally intact anal sphincter when **all** of the following criteria is met:
      - a. A test of percutaneous stimulation was effective, defined as at least 50% sustained (more than one week) improvement in symptoms;
      - b. Condition is not related to anorectal malformation (e.g., congenital anorectal malformation, defects of the external anal sphincter over 60 degrees, visible sequelae of pelvic radiation, active anal abscesses and fistulae) and/or chronic inflammatory bowel disease;
      - c. Incontinence is not related to another neurologic condition such as peripheral neuropathy or complete spinal cord injury;
      - d. Has none of the following contraindications:
        - i. mechanical outlet obstruction;
        - ii. diathermy use (shortwave, microwave, ultrasound);
        - iii. inadequate response to test stimulation or inability to operate the device;
    2. Sphincter repair (sphincteroplasty) when there is a defined defect of the external anal sphincter;
    3. Artificial bowel sphincter (Acticon Neosphincter) when **all** of the following criteria is met:
      - a. Age  $\geq$  18 years;
      - b. Failure of, or not a candidate for, medical interventions or surgical sphincter repair;

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

- c. Incontinence is not complicated by an irreversibly obstructed proximal segment of bowel;
  - d. Absence of any physical or mental illness that would increase surgical risk;
  - 4. Colostomy, as last resort, when all other treatments have failed or are contraindicated.
- II.** It is the policy of WellCare of North Carolina® that the following procedures have not been proven effective for the treatment of fecal incontinence, although they continue to be evaluated in clinical studies:
- A. Transanal radiofrequency therapy (Secca procedure);
  - B. Injectable bulking agents [e.g., dextranomer/hyaluronic acid (Solesta)];
  - C. Anal electrical stimulation;
  - D. Posterior tibial nerve stimulation;
  - E. Vaginal bowel control (e.g, Eclipse system);
  - F. Sacral nerve stimulation for the treatment of chronic constipation or chronic pelvic pain.

#### Background

Treatment of fecal incontinence is challenging. The goal of treatment is to restore continence and to improve the quality of life. Dietary and medical management are recommended as first-line therapy for patients with fecal incontinence. If fecal incontinence is a result of or in conjunction with anatomic defects (e.g., rectovaginal fistula, rectal or hemorrhoidal prolapse etc.), the defects should be corrected first as this often improves or eliminates the incontinence.

Sacral neuromodulation is thought to modulate rectal sensation by activating or deactivating chemical mediating receptors, stimulating the afferent pathway, and changing brain activity relevant to the continence. Sacral neuromodulation has consistently shown to result in a reduction in frequency of fecal incontinence episodes and may be considered for incontinent patients with and without sphincter defects. Sphincter repair (sphincteroplasty) may be offered to symptomatic patients with a defined defect of the external anal sphincter. Implantation of an artificial bowel sphincter remains an effective tool for select patients with severe fecal incontinence; however, its use is limited by complications including explanation in up to one-third of patients.<sup>2</sup>

Injectable bulking agents [e.g., dextranomer/hyaluronic acid (Solesta)] have been investigated for the treatment of fecal incontinence. However, evidence in the peer review literature evaluating this treatment is limited. There is a paucity of randomized, controlled trials and studies are limited by their small study sizes. A prospective multicenter trial of 136 patients with fecal incontinence who received non-animal stabilized hyaluronic acid/dextranomer (NASHA Dx) bulking agent reported it provided a significant improvement of fecal incontinence symptoms in a majority of patients and this effect was stable during the course of the follow-up and maintained for 3 years.<sup>3</sup> Long-term data is lacking, however, regarding the durability of this treatment.

Transanal radiofrequency therapy (e.g., Secca procedure) is another procedure proposed for the treatment of fecal incontinence). This procedure uses thermo-controlled delivery of radiofrequency energy to the anal canal. The reported evidence is relatively sparse and has relevant limitations. Most studies have been small single-center series with short to mid-term follow-up.

The Eclipse System (Pelvalon Inc) is a nonsurgical vaginal bowel-control system for the treatment of fecal incontinence in women 18 to 75 years old who have had four or more FI

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

episodes in a two-week period. The device includes an inflatable balloon, which is placed in the vagina. Upon inflation, the balloon exerts pressure through the vaginal wall onto the rectal area, thereby reducing the number of FI episodes. The device is initially fitted and inflated by a clinician (with the use of a pump) and after proper fitting, the patient can inflate and deflate the device at home as needed. The device was granted FDA approval through the de novo classification process based on non-clinical testing as well as a clinical trial of 61 women with FI treated with the device. The trial showed that after one month almost 80 percent of women in the study experienced a 50 percent decrease in the number of FI episodes while using the device, as compared to baseline. Studies to date are limited by size and lack of long term evidence.

#### *American Society of Colon and Rectal Surgeons (ASCRS)*

In their most recent guidelines on the treatment of fecal incontinence, the ASCRS assigns strong recommendations in favor of sacral neuromodulation, and sphincteroplasty based upon moderate quality of evidence. The ASCRS reports that injection of biocompatible bulking agents into the anal canal may help to decrease episodes of passive fecal incontinence. However, based upon moderate-quality evidence, this is a weak recommendation. The ASCRS notes that although modest improvements have been reported in short-term outcomes, long-term follow-up with regard to safety and efficacy awaits further experience.

The ASCRS guideline states the application of temperature-controlled radiofrequency energy to the sphincter complex may be used to treat fecal incontinence. However, this is also a weak recommendation based on moderate-quality of evidence. The ASCRS reports that most studies have been small single-center series with short-term follow-up. Per the ASCRS, “Because of the limitations in the available data, alternative treatments should be pursued before considering radiofrequency energy delivery.”<sup>1</sup>

#### *American College of Gastroenterology (ACG)*

Regarding minimally invasive procedures for the treatment of fecal incontinence, the ACG concluded that minimally invasive procedures such as injectable anal bulking agents may have a role in patients with fecal incontinence who do not respond to conservative therapy. However, they note this is a weak recommendation based on moderate-quality of evidence. The ACG reported that there is insufficient evidence to recommend radiofrequency ablation treatment to the anal sphincter (SECCA) at this time.<sup>4</sup>

#### *National Institute for Health and Clinical Excellence*

An interventional procedure guidance on injectable bulking agents for fecal incontinence concluded the current evidence on the safety and efficacy of injectable bulking agents for fecal incontinence does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research, which should take place in the context of a clinical trial or formal audit protocol that includes information on well-defined patient groups.<sup>5</sup>

#### *American College of Obstetricians and Gynecologists (ACOG)*<sup>25</sup>

A practice bulletin on fecal incontinence concluded that anal sphincter bulking agents may be effective in decreasing fecal incontinence episodes up to 6 months and can be considered as a short-term treatment option for fecal incontinence in women who have failed more conservative treatments. However, this was based on limited or inconsistent scientific evidence (Level B).

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

#### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT®* Codes	Description
46750	Sphincteroplasty, anal, for incontinence or prolapse; adult
46751	Sphincteroplasty, anal, for incontinence or prolapse; child
46760	Sphincteroplasty, anal, for incontinence or prolapse, adult; muscle transplant
46761	Sphincteroplasty, anal, for incontinence or prolapse, adult; levator muscle imbrication (Park posterior anal repair)
46999	Unlisted procedure, anus
64561	Percutaneous implantation of neurostimulator electrodes; sacral nerve (transforaminal placement) including image guidance, if performed
64581	Incision for implantation of neurostimulator electrodes; sacral nerve (transforaminal placement)
64585	Revision or removal of peripheral neurostimulator electrodes
64590	Insertion and replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
64595	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter [eg. contact group(s), interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming
95971	Electronic analysis of implanted neurostimulator pulse generator /transmitter system [e.g. contact group(s), interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters] by physician or other qualified health care professional; with simple spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional
95972	Electronic analysis of implanted neurostimulator pulse generator /transmitter [eg, contact group (s), interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

CPT® Codes	Description
	parameters] by physician or other qualified health care professional; with complex spinal cord or peripheral nerve (eg, sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional

HCPCS® Codes	Description
A4290	Sacral nerve stimulation test lead, each
A4335	Incontinence supply; miscellaneous
E0745	Neuromuscular stimulator, electronic shock unit
L8680	Implantable neurostimulator electrode, each
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8682	Implantable neurostimulator radiofrequency receiver
L8683	Radiofrequency transmitter (internal) for use with implantable neurostimulator radiofrequency receiver
L8684	Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension
L8689	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only

#### HCPCS codes that do not support coverage criteria

HCPCS® Codes	Description
L8605	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies

#### ICD-10-CM Diagnosis Codes that Support Coverage Criteria

+ Indicates a code(s) requiring an additional character

ICD-10-CM Code	Description
R15.0-R15.9	Fecal incontinence

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

Reviews, Revisions, and Approvals	Date	Approval Date
Original approval date	03/21	05/21
Updated criteria in Sections C.1.b, and C.1.c. Updated investigational verbiage in Section D. Reviewed CPT, HCPCS, and ICD-10-CM codes. Added HCPCS code that does not support medical necessity criteria. References reviewed and updated.	05/22	

#### References

1. Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal Incontinence. *Dis Colon Rectum*. 2015;58(7):623-636. doi:10.1097/DCR.0000000000000397.
2. Robson K.M, Lembo A.J. Fecal incontinence in adults: Management. UpToDate. [www.updtodate.com](http://www.updtodate.com). Updated September 28, 2020. Accessed June 25, 2021.
3. Mellgren A, Matzel KE, Pollack J, et al. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence. *Neurogastroenterol Motil*. 2014;26(8):1087-1094. doi:10.1111/nmo.12360.
4. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. *Am J Gastroenterol*. 2014 Aug;109(8):1141-57; (Quiz) 1058. doi: 10.1038/ajg.2014.190. Epub 2014 Jul 15. PMID: 25022811.
5. National Institute for Health and Clinical Excellence. Injectable bulking agents for fecal incontinence. <https://www.nice.org.uk/guidance/ipg210/resources/injectable-bulking-agentsfor-faecal-incontinence-pdf-1899865208328901> Published February 28, 2007. Updated March 2010. Accessed June 25, 2021.
6. Hayes Health Technology Brief. Solesta (NASHA Dx; Q-Med AB) for Treatment of Fecal Incontinence. Oct 2014. (archived November 16, 2017). Accessed June 25, 2021.
7. Sanchez JE, Brenner DM, Franklin H, Yu J, Barrett AC, Paterson C. Validity of the  $\geq 50\%$  Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence. *Clin Transl Gastroenterol*. 2015;6(1):e70. Published 2015 Jan 15. doi:10.1038/ctg.2014.20.
8. Lefebure B, Tuech JJ, Bridoux V, Gallas S, Leroi AM, Denis P, Michot F. Temperaturecontrolled radio frequency energy delivery (Secca procedure) for the treatment of fecal incontinence: results of a prospective study. *Int J Colorectal Dis*. 2008 Oct;23(10):993-7. doi: 10.1007/s00384-008-0514-0. Epub 2008 Jul 2. PMID: 18594840.
9. Ruiz D, Pinto RA, Hull TL, Efron JE, Wexner SD. Does the radiofrequency procedure for fecal incontinence improve quality of life and incontinence at 1-year follow-up? *Dis Colon Rectum*. 2010 Jul;53(7):1041-6. doi: 10.1007/DCR.0b013e3181deff8. PMID: 20551757.
10. Felt-Bersma RJ. Temperature-controlled radiofrequency energy in patients with anal incontinence: an interim analysis of worldwide data. *Gastroenterol Rep (Oxf)*. 2014 May;2(2):121-5. doi: 10.1093/gastro/gou016. Epub 2014 Apr 12. PMID: 24759350; PMCID: PMC4020122.
11. Lam TJ, Visscher AP, Meurs-Szojda MM, Felt-Bersma RJ. Clinical response and sustainability of treatment with temperature-controlled radiofrequency energy (Secca) in patients with fecal incontinence: 3 years follow-up. *Int J Colorectal Dis*. 2014

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

- Jun;29(6):755-61. doi: 10.1007/s00384-014-1882-2. Epub 2014 May 8. PMID: 24805249.
12. Takahashi-Monroy T, Morales M, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, Zarate X, Bada O, Velasco L. SECCA procedure for the treatment of fecal incontinence: results of five-year follow-up. *Dis Colon Rectum*. 2008 Mar;51(3):355-9. doi: 10.1007/s10350-007-9169-0. Epub 2008 Jan 19. PMID: 18204954.
  13. Efron JE, Corman ML, Fleshman J, Barnett J, Nagle D, Birnbaum E, Weiss EG, Nogueras JJ, Sligh S, Rabine J, Wexner SD. Safety and effectiveness of temperature-controlled radiofrequency energy delivery to the anal canal (Secca procedure) for the treatment of fecal incontinence. *Dis Colon Rectum*. 2003 Dec;46(12):1606-16; discussion 1616-8. doi: 10.1007/BF02660763. PMID: 14668584.
  14. Sanchez JE, Brenner DM, Franklin H, Yu J, Barrett AC, Paterson C. Validity of the  $\geq 50\%$  Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence. *Clin Transl Gastroenterol*. 2015 Jan 15;6(1):e70. doi: 10.1038/ctg.2014.20. PMID: 25588523; PMCID: PMC4418408.
  15. La Torre F, de la Portilla F. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence. *Colorectal Dis*. 2013 May;15(5):569-74. doi: 10.1111/codi.12155. PMID: 23374680.
  16. Franklin H, Barrett AC, Wolf R. Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinence. *Clin Exp Gastroenterol*. 2016 Mar 2;9:41-7. doi: 10.2147/CEG.S95238. PMID: 27042136; PMCID: PMC4780737.
  17. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M; NASHA Dx Study Group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. *Lancet*. 2011 Mar 19;377(9770):997-1003. doi: 10.1016/S0140-6736(10)62297-0. PMID: 21420555.
  18. Frascio M, Stabilini C, Casaccia M, Testa T, Fornaro R, Parodi MC, Marrone C, Gianetta E, Mandolino F. Radiofrequency Procedure (SECCA®) for Fecal Incontinence: One-Year Experience. *Surg Technol Int*. 2017 Jul 25;30:97-101. PMID: 28277597.
  19. Visscher AP, Lam TJ, Meurs-Szojda MM, Felt-Bersma RJF. Temperature-Controlled Delivery of Radiofrequency Energy in Fecal Incontinence: A Randomized Sham-Controlled Clinical Trial. *Dis Colon Rectum*. 2017 Aug;60(8):860-865. doi: 10.1097/DCR.0000000000000861. PMID: 28682972.
  20. Al-Bayati I, Saadi M, Elhanafi S, McCallum RW. Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies. *Am J Med Sci*. 2017 Nov;354(5):476-479. doi: 10.1016/j.amjms.2017.09.001. Epub 2017 Sep 5. PMID: 29173359.
  21. van der Wilt AA, Giuliani G, Kubis C, van Wunnik BPW, Ferreira I, Breukink SO, Lehur PA, La Torre F, Baeten CGMI. Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients with faecal incontinence. *Br J Surg*. 2017 Aug;104(9):1167-1176. doi: 10.1002/bjs.10590. PMID: 28703936.
  22. Richter HE, Matthews CA, Muir T, Takase-Sanchez MM, Hale DS, Van Drie D, Varma MG. A vaginal bowel-control system for the treatment of fecal incontinence. *Obstet Gynecol*. 2015 Mar;125(3):540-547. doi: 10.1097/AOG.0000000000000639. PMID: 25730213.

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

23. Varma MG, Matthews CA, Muir T, Takase-Sanchez MM, Hale DS, Van Drie D, Richter HE. Impact of a Novel Vaginal Bowel Control System on Bowel Function. *Dis Colon Rectum*. 2016 Feb;59(2):127-31. doi: 10.1097/DCR.0000000000000517. PMID: 26734971.
24. Hayes Health Technology Brief. Staged Approach to Sacral Nerve Stimulation for Treatment of Fecal Incontinence. Published December 29, 2015. (archived January 29, 2021) Accessed June 25, 2021.
25. ACOG Practice Bulletin No. 210: Fecal Incontinence. *Obstet Gynecol*. 2019 Apr;133(4):e260-e273. doi: 10.1097/AOG.00000000000003187. Erratum in: *Obstet Gynecol*. 2019 Nov;134(5):1121. PMID: 30913197.
26. Local coverage article: billing and coding: sacral nerve stimulation for urinary and fecal incontinence (A53017). Centers for Medicare and Medicaid Services website. <http://www.cms.hhs.gov/mcd/search.asp>. Published October 1, 2015 (revised January 1, 2020). Accessed June 25, 2021.
27. Ellsworth, P.I. Sacral nerve stimulator. Medscape website. <https://emedicine.medscape.com/article/2036909-overview#a1>. Published December 9, 2015 (updated June 7, 2018). Accessed June 25, 2021.

### **North Carolina Guidance**

#### *Eligibility Requirements*

- a. An eligible beneficiary shall be enrolled in either:
  1. the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise); or
  2. the NC Health Choice (NCHC is NC Health Choice program, unless context clearly indicates otherwise) Program on the date of service and shall meet the criteria in this policy.
- b. Provider(s) shall verify each Medicaid or NCHC beneficiary's eligibility each time a service is rendered.
- c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.
- d. Following is only one of the eligibility and other requirements for participation in the NCHC Program under GS 108A-70.21(a): Children must be between the ages of 6 through 18.

#### *EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age*

- a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]  
Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary's physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary's right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

1. that is unsafe, ineffective, or experimental or investigational.
2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider's documentation shows that the requested service is medically necessary "to correct or ameliorate a defect, physical or mental illness, or a condition" [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary's health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

#### **EPSDT and Prior Approval Requirements**

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
2. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below:

*NCTracks Provider Claims and Billing Assistance Guide:*

<https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html>

*EPSDT provider page:* <https://medicaid.ncdhhs.gov/>

EPSDT does not apply to NCHC beneficiaries.

#### *Provider(s) Eligible to Bill for the Procedure, Product, or Service*

To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

- a. meet Medicaid or NCHC qualifications for participation;
- b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and
- c. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

#### *Compliance*

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

Provider(s) shall comply with the following in effect at the time the service is rendered:

- a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and
- b. All NC Medicaid's clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

#### *Claims-Related Information*

Provider(s) shall comply with the, NC Tracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid's clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid and NCHC:

- a. Claim Type - as applicable to the service provided:  
Professional (CMS-1500/837P transaction)  
Institutional (UB-04/837I transaction)  
Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.
- b. International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) - Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.
- c. Code(s) - Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy. If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

#### *Unlisted Procedure or Service*

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions For Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service

- d. Modifiers - Providers shall follow applicable modifier guidelines.
- e. Billing Units - Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).
- f. Co-payments -  
For Medicaid refer to Medicaid State Plan:  
<https://medicaid.ncdhhs.gov/get-involved/nc-health-choice-state-plan>  
For NCHC refer to NCHC State Plan:

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

<https://medicaid.ncdhhs.gov/get-involved/nc-health-choice-state-plan>

- g. Reimbursement - Provider(s) shall bill their usual and customary charges. For a schedule of rates, refer to: <https://medicaid.ncdhhs.gov/>.

#### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

## CLINICAL POLICY

### FECAL INCONTINENCE TREATMENTS

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.